Adverse events associated with mTOR inhibitors

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Temsirolimus: a safety and efficacy review

(2012) Ronald M. Bukowski   Expert Opinion On Drug Safety

A drug safety evaluation of everolimus in kidney transplantation

(2012) Hallvard Holdaas et al.   Expert Opinion On Drug Safety

Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation

(2012) Björn Nashan et al.   TRANSPLANTATION

Mammalian Target of Rapamycin (mTOR) Inhibitors

(2011) Sofia Sofroniadou et al.   DRUG SAFETY

Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment

(2011) Barry Kahan   Expert Opinion On Drug Safety

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice

(2011) Markus Gödel et al.   JOURNAL OF CLINICAL INVESTIGATION

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus

(2011) Jose Pablo Maroto et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

(2011) Klemens Budde et al.   LANCET

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Common toxicities of mammalian target of rapamycin inhibitors

(2011) Scott A. Soefje et al.   Targeted Oncology

mTOR inhibitor–associated proteinuria in kidney transplant recipients

(2011) Fritz Diekmann et al.   Transplantation Reviews

mTOR inhibitor-associated dermatologic and mucosal problems

(2010) Josep M. Campistol et al.   CLINICAL TRANSPLANTATION

Structure of the Human mTOR Complex I and Its Implications for Rapamycin Inhibition

(2010) Calvin K. Yip et al.   MOLECULAR CELL

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial

(2010) Jacques Dantal et al.   TRANSPLANT INTERNATIONAL

Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study

(2009) Y. Lebranchu et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The Multifunctional Role of mTOR in Innate Immunity: Implications for Transplant Immunity

(2009) M. D. Säemann et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Delayed Graft Function and Wound Healing Complications After Deceased-Donor Kidney Transplantation Is not Affected by De Novo Everolimus

(2009) Laetitia Albano et al.   TRANSPLANTATION

Mammalian Target of Rapamycin and Diabetes: What Does the Current Evidence Tell Us?

(2009) B. Vodenik et al.   TRANSPLANTATION PROCEEDINGS

Sirolimus May Reduce Fertility in Male Renal Transplant Recipients

(2008) J. Zuber et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

(2008) B. I. Rini   CLINICAL CANCER RESEARCH

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development

(2008) Monica Mita et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients

(2008) O. Johnston et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A

(2008) Christian Faul et al.   NATURE MEDICINE

Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis

(2008) John J. Bissler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA